Abstract

. Colver A.F., Nevantaus H., Macdougall C.F. Cant A.J. ( 2005 ) , 94 , 689 – 695 . Aim Medical and lay concerns about food allergy are increasing. Whilst food allergy may be becoming more common, fatal reactions to food in childhood are very rare and their rate is not changing. We sought to establish how common severe reactions are.Methods Prospective survey, 1998–2000, of hospital admissions for food‐allergic reactions – conducted primarily through the British Paediatric Surveillance Unit, covering the 13 million children in the UK and Ireland.Results A total of 229 cases reported by 176 physicians in 133 departments, yielding a rate of 0.89 hospital admissions per 100 000 children per year. Sixty‐five per cent were male, 41% were under 4 years and 60% started at home. Main allergens were peanut (21%), tree nuts (16%), cow's milk (10%) and egg (7%). Main symptoms were facial swelling (76%), urticaria (69%), respiratory (66%), shock (13%), gastrointestinal (4%). Fifty‐eight cases were severe. Three were fatal, six near fatal, and 8 of these 9 had asthma with wheeze being the life‐threatening symptom. Three near‐fatal cases received excess intravenous epinephrine. None of the non‐fatal reactions resulted in mental or physical impairment. Seven of 171 non‐severe and 6/58 severe cases might have had a worse outcome if epinephrine auto‐injectors had been unavailable. Six of the severe cases might have benefited if auto‐injectors had been more widely prescribed.Conclusion In the UK and Ireland, the incidence of severe reactions is low. The study highlights that: (1) asthma is a strongly significant risk factor for a severe reaction and therefore warrants optimal management; (2) severe wheeze is a prominent feature of severe reactions and warrants optimal management; and (3) intravenous epinephrine should be used with great care if needed. Epinephrine auto‐injectors do not always prevent death, but our study design and data do not allow a definite statement about whether overall they are beneficial.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.